• If you are wondering whether Edwards Lifesciences stock offers good value at its current price, the key question is how that price compares with what the business may reasonably be worth.
• The stock most recently closed at US$89.72, with returns of 2.7% over the past week, 2.5% over the last month, 5.1% year to date, and 16.3% over the past year. However, 3 year and 5 year returns are lower, at a decline of 2.5% and 14.4% respectively.
• Recent coverage around Edwards Lifesciences has focused on its role in the medical technology space and how investors weigh its long term growth prospects against current pricing. This context helps explain why the stock's positive shorter term returns contrast with weaker multi year performance, as sentiment can shift when expectations or perceived risks change.
• Simply Wall St currently assigns Edwards Lifesciences a value score of 1 out of 6, which means it screens as undervalued in only one of six valuation checks. The rest of this article will break down those methods before turning to a broader way of thinking about valuation that goes beyond a single score.

Edwards Lifesciences scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Edwards Lifesciences Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what Edwards Lifesciences stock might be worth by projecting future cash flows and discounting them back to today using a required rate of return. It is essentially a way of translating future cash generation into a single present value figure.

For Edwards Lifesciences, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is about $1.05b. Analyst estimates feed into the earlier years of the forecast, with Simply Wall St extrapolating further out. For example, projected free cash flow for 2028 is $1.93b, and the model continues with annual projections out to 2035.

When these projected cash flows are discounted back to today, the DCF model produces an estimated intrinsic value of $91.82 per share. Compared with the recent share price of $89.72, this implies Edwards Lifesciences is 2.3% undervalued, which is a very small gap.

Result: ABOUT RIGHT

Edwards Lifesciences is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Edwards Lifesciences Price vs Earnings

For a profitable company like Edwards Lifesciences, the P/E ratio is a useful way to think about value because it links what you pay directly to the earnings the business is currently generating. Investors typically accept a higher or lower P/E depending on how they view the stock's growth potential and risk profile, with higher expected growth or lower perceived risk often supporting a higher "normal" P/E.

Edwards Lifesciences currently trades on a P/E of 48.03x. This compares with an average P/E of 24.80x for peers and 24.97x for the wider Medical Equipment industry. On these simple comparisons, the stock trades at a higher multiple than both its peer group and the sector.

Simply Wall St also provides a proprietary "Fair Ratio" of 29.06x. This is an estimate of what Edwards Lifesciences' P/E might be given factors such as its earnings growth profile, industry, profit margins, market capitalization and specific risks. Because it adjusts for these company specific characteristics, the Fair Ratio can be more informative than a straight comparison with peer or industry averages.

Comparing the current P/E of 48.03x with the Fair Ratio of 29.06x suggests Edwards Lifesciences stock screens as overvalued on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Edwards Lifesciences Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you connect your story about Edwards Lifesciences with the numbers by setting your own assumptions for future revenue, earnings and margins. The platform then turns these into a forecast, a fair value, and a clear buy or sell framework by comparing that fair value with the current price. It updates automatically when new news or earnings arrive. For example, one investor might build an optimistic Edwards Lifesciences Narrative that lines up with the higher US$110 analyst target, while another uses more cautious assumptions closer to US$84. You can see both side by side on the Community page to decide which story and valuation feel more realistic to you.

Do you think there's more to the story for Edwards Lifesciences? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.